Subscribe to Search results

The Northern Regional Health Authority's position on funding additional cost was yet to be declared.

Published on:

Armour Pharmaceutical Company Limited in the UK was incorporated in 1959. It had several changes in name and parent company and was dissolved in 2010.

Published on:

From mid March 1985 Cutter had taken the strategic decision to stop selling unheated stock to UK centres.

Published on:

An internal report of Cutter speaking of the UK sales position recorded that a small "short dated batch" of non-heat-treated concentrate was sold during the previous month.

Published on:

An inventory for Alpha UK showed that just under 25% of its current stocks remained non-heat-treated at the start of September 1985.

Published on:

The response by UK doctors to steps taken in the US was mixed. Dr Harris reported that Dr Rotblat "had been summoned to the Chief Medical Officer of the DHSS to answer questions concerning our product recall and discussions held in March concerning potential problems with Armour Factorate HT."

Published on:

Cutter had shown a hepatitis rate from heat treated products of 20% in "virgin or near-virgin" patients in studies in Bonn and Freiburg, and Hyland had a rate of 80% in a multi-centre study conducted by Dr Pier Mannucci.

Published on:

The first batch of Cutter product, Koate HT, which was made from 100% tested plasma was shipped to the UK in January/February 1986.

Published on:

An internal Cutter memo recorded that although "Cutter will only sell 100% screened material" nonetheless "some Centre Directors are happy to use up their existing stock of unscreened Koate HT."

Published on:

Dr Rotblat was intending to discuss the matter of seroconversion further with Robert Christie of Armour to ascertain if he had any possible new evidence.

Published on:

In a paper on the safety of heat-treated Factor 8 prepared by Dr Rotblat, it was reported there were two cases of seroconversion after treatment with heat-treated Factorate from a batch known to contain a donor who had AIDS.

Published on:

Gilbert C et al published an article in "The Lancet" describing a case of seroconversion of AIDS in a person with mild haemophilia after administration of high doses of heat treated Factor 8 concentrate.

Published on:

Professor Arthur Bloom wrote to the DHSS to urge that heat-treated products be licensed so as to be freely available.

Published on:

Professor Bloom was assured by the DHSS that prompting "the appropriate manufacturers" to apply for abridged product licences to ensure the supply of heat-treated product was a "high priority item".

Published on:

The meetings of the AIDS group of UKHCDO directors agreed to recommend that only heat-treated product should be used thereafter.

Published on:

EAGA's discussion of cases found the Lewisham patient (referred to in the minutes as the patient with mild haemophilia who had not received treatment since 1980) could not be explained by late seroconversion.

Published on:

The Biologicals Sub-Committee of the Committee on Safety of Medicines decided that there was "insufficient evidence for action to be taken on any specific product" but that "close surveillance should be maintained on the two possible cases of HTLV-III transmission in recipients of Armour material."

Published on:

Dr Jones wrote to colleagues enclosing a copy of his conference paper and explaining his decision to present the information about possible seroconversions at the conference.

Published on:

The CBLA announced that they planned to heat all Factor 8 manufactured at BPL/PFL from April 1985.

Published on:

The record of the 27 November meeting of the Working Group on AIDS described it as having gone "reasonable [sic] well"; whereas other reports expressed a significantly different viewpoint.

Published on: